Literature DB >> 6426549

Stabilization of thrombin-activated porcine factor VIII:C by factor IXa phospholipid.

P Lollar, G J Knutson, D N Fass.   

Abstract

The activation of porcine factor X by an enzymatic complex consisting of activated factor IX (factor IXa), thrombin-activated factor VIII:C (factor VIII:Ca), phospholipid vesicles, and calcium was studied in the presence of an irreversible inhibitor of factor Xa, 5-dimethylamino-naphthalene-1-sulfonyl-glutamyl-glycyl-arginyl- chloro met hyl ketone ( DEGR -CK). The formation of factor Xa was measured continuously by monitoring the increase in solution fluorescence intensity that occurs upon formation of DEGR -factor Xa. Omission of any component from the enzymatic complex reduced the reaction rate to a negligible level. In the presence of fixed excess factor IXa, the velocity of factor X activation was linearly dependent on the concentration of factor VIII:C, and thus, provided a plasma-free assay of factor VIII:C. Activation of factor VIII:C by 0.1 NIH U/ml thrombin in the presence of factor IXa, phospholipid vesicles, and calcium, followed at variable time intervals by the addition of factor X and DEGR -CK, was complete within 5 min, as judged by the fluorometric assay, and resulted in little or no loss of factor VIII:C activity over a period of 20 min; whereas, activation in the absence of either IXa or phospholipid vesicles decreased the half-life of factor VIII:C to approximately 5 min. Analysis of 125I-factor VIII:C-derived activation peptides by sodium dodecyl sulfate polyacrylamide gel radioelectrophoresis revealed identical results, regardless of whether factor IXa and/or phospholipid vesicles were included in the activation, suggesting that the lability of factor VIII:Ca is not due to a major alteration of its primary structure. We conclude that the activated porcine factor VIII:C molecule is stabilized markedly because of its interaction with factor IXa and phospholipid.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6426549

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  The "normal" factor VIII concentration in plasma.

Authors:  Saulius Butenas; Behnaz Parhami-Seren; Anetta Undas; David N Fass; Kenneth G Mann
Journal:  Thromb Res       Date:  2010-05-07       Impact factor: 3.944

2.  Contribution of A1 subunit residue Q316 in thrombin-activated factor VIII to A2 subunit dissociation.

Authors:  Ernest T Parker; Pete Lollar
Journal:  Biochemistry       Date:  2007-08-04       Impact factor: 3.162

3.  Identification of residues contributing to A2 domain-dependent structural stability in factor VIII and factor VIIIa.

Authors:  Hironao Wakabayashi; Philip J Fay
Journal:  J Biol Chem       Date:  2008-02-25       Impact factor: 5.157

Review 4.  Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology.

Authors:  R J Kaufman
Journal:  Ann Hematol       Date:  1991-09       Impact factor: 3.673

5.  Identification of residues in the 558-loop of factor VIIIa A2 subunit that interact with factor IXa.

Authors:  Indu Jagannathan; H Travis Ichikawa; Tricia Kruger; Philip J Fay
Journal:  J Biol Chem       Date:  2009-09-28       Impact factor: 5.157

6.  Structural model of porcine factor VIII and factor VIIIa molecules based on scanning transmission electron microscope (STEM) images and STEM mass analysis.

Authors:  M W Mosesson; D N Fass; P Lollar; J P DiOrio; C G Parker; G J Knutson; J F Hainfeld; J S Wall
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

7.  Factor VIIIa A2 subunit shows a high affinity interaction with factor IXa: contribution of A2 subunit residues 707-714 to the interaction with factor IXa.

Authors:  Amy E Griffiths; Ivan Rydkin; Philip J Fay
Journal:  J Biol Chem       Date:  2013-04-11       Impact factor: 5.157

8.  Inhibition of human factor VIIIa by anti-A2 subunit antibodies.

Authors:  P Lollar; E T Parker; J E Curtis; S L Helgerson; L W Hoyer; M E Scott; D Scandella
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

9.  Potency and mass of factor VIII in FVIII products.

Authors:  S Butenas; B Parhami-Seren; M T Gissel; E D Gomperts; D N Fass; K G Mann
Journal:  Haemophilia       Date:  2008-08-06       Impact factor: 4.287

Review 10.  The molecular basis of factor V and VIII procofactor activation.

Authors:  R M Camire; M H A Bos
Journal:  J Thromb Haemost       Date:  2009-09-18       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.